secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cartesian Therapeutics, Inc. (RNAC)
CIK:        0001453687
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001453687-25-000123
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cartesian reports 100% LLDAS response in Phase 2 SLE; expands Descartes-08 into myositis
--------------------------------------------------------------------------------

- 100% LLDAS response at Month 3 (n=3) in Phase 2 SLE trial; 2 of 3 achieved DORIS remission.
- No CRS or ICANS observed; outpatient administration without lymphodepleting chemotherapy.
- Plans to pause SLE and Descartes-15 (multiple myeloma) to prioritize MG Phase 3 and myositis.
- Myositis seamless adaptive Phase 2 trial expected to start 1H26; IND filing by end 2025.
- Cash runway extended to mid-2027 supporting MG Phase 3 and myositis trial initiation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453687/000145368725000123/0001453687-25-000123-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453687/000145368725000123/rnac-20251113.htm
  HTML page:      https://secwatch.observer/filing/0001453687-25-000123

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer